Rapid joint pain and stiffness relief
Human RCTs demonstrate NEM® (500 mg/day) produces significant reductions in joint pain within 7 days and stiffness within 10 days — substantially faster than glucosamine, chondroitin, or collagen peptides individually. The rapid onset distinguishes NEM® from other joint ingredients and is attributed to the bioavailable natural matrix format.
Exercise-induced joint discomfort reduction
A clinical study in healthy active adults showed NEM® significantly reduced exercise-induced joint pain and discomfort in the knees, hips, and shoulders. Flexibility improvements were observed after 4 weeks of supplementation, suggesting structural improvements beyond acute pain relief.
Multiple joint-support compounds in one ingredient
NEM® naturally contains the full matrix of joint structural components — type I, V, and X collagen, elastin, glucosamine, chondroitin sulfate, and hyaluronic acid — in naturally occurring ratios. This whole-food matrix may provide superior bioavailability compared to isolated synthetic forms of these compounds.
Connective tissue and skin health
The collagen and elastin in NEM® support not just joint cartilage but also connective tissue throughout the body — including skin, tendons, and ligaments. Regular supplementation may improve skin elasticity and reduce the appearance of fine lines in addition to joint benefits.
Oral tolerance induction via type II collagen mechanism
NEM® contains native (undenatured) collagen that interacts with gut-associated lymphoid tissue (GALT) to induce oral tolerance — a process where the immune system is trained not to attack joint collagen as a foreign antigen. This mechanism, established for UC-II collagen, reduces autoimmune-mediated joint inflammation.
Direct GAG and hyaluronic acid supplementation
NEM® delivers bioavailable glucosamine, chondroitin sulfate, and hyaluronic acid — the primary structural glycosaminoglycans of articular cartilage and synovial fluid. These compounds support cartilage proteoglycan synthesis, synovial fluid viscosity, and joint lubrication simultaneously.
TGF-β and chondrocyte stimulation
NEM® contains transforming growth factor-β (TGF-β), a growth factor that stimulates chondrocyte (cartilage cell) proliferation and proteoglycan synthesis. This anabolic effect on cartilage cells supports cartilage maintenance and repair rather than just symptom management.
Randomized, double-blind, multi-center trial of NEM® (500 mg/day) vs. placebo in 67 patients with knee and hip osteoarthritis for 8 weeks.
67 adults with knee and hip osteoarthritis. 8-week intervention.
NEM® significantly reduced pain at 10 days (-12.8% vs. +0.3% placebo) and stiffness at 7 days (-15.6% vs. +8.3% placebo). Improvements continued through week 8. Rapid onset of benefit distinguishes NEM® from slower-acting joint supplements.
Randomized, double-blind, placebo-controlled trial of NEM® (500 mg/day) in 29 healthy active adults experiencing exercise-induced joint discomfort for 4 weeks.
29 healthy active adults with exercise-induced joint discomfort. 4-week intervention.
NEM® supplementation significantly reduced exercise-induced joint pain and discomfort vs. placebo after 4 weeks. Improvements in joint flexibility also observed. Supports NEM® for active population joint health maintenance, not just OA treatment.